Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

7:36 AM ET 8-K
Financial Results MasterCraft Boat Holdings, Inc. MCFT

MasterCraft Boat Holdings Financial Results

MasterCraft Boat Holdings reported financial results for the first three months of its transition period, with net sales increasing 123.4% to $154.1 million. The growth was driven by the recent merger with Marine Products, which contributed $59.3 million in incremental sales, alongside a 37.4% increase in legacy business sales. The company is transitioning its fiscal year-end to December 31 following the merger completion.

Term
3 months ended Oct 4, 2026

“We delivered results above our expectations in the first quarter of the Transition Period, with total company net sales growing more than 120% year-over-year. Importantly, our legacy business net sales grew 37% and delivered Adjusted EBITDA growth of nearly 140%, reflecting the deliberate product, commercial, and operational actions we have taken across our business to drive premium mix, clean channels, and reduce costs.”

Brad Nelson, Chief Executive Officer

“The success of the next-generation X-Series is a clear example of the strength of our product and portfolio strategy and our ability to translate a deep understanding of our consumers into products that resonate in the market. Combined with our ongoing cost, productivity, and quality initiatives, those actions are driving stronger earnings and margin performance.”

Brad Nelson, Chief Executive Officer
7:35 AM ET 8-K
Financial Results Xilio Therapeutics, Inc. XLO

Xilio Therapeutics Financial Results

Xilio Therapeutics reported financial results for the third quarter ended September 30, 2026, highlighting the dosing of the first patient in its Phase 1/2 trial for XTX501. The company ended the quarter with $45.1 million in cash and cash equivalents, which it expects will fund operations into the second quarter of 2027.

Term
Q3 2026

“In the third quarter, we initiated our Phase 1/2 clinical trial for XTX501, a PD-1/masked IL-2 bispecific that we believe has the potential to become a foundational backbone immunotherapy regimen for solid tumors.”

René Russo, Pharm.D., president and chief executive officer of Xilio
7:34 AM ET 10-Q
Financial Results Arbutus Biopharma Corp ABUS

Arbutus Biopharma Q3 2026 Results: Turns Profitable, Net Income $59.1M

Arbutus Biopharma reported a significant net income of $223.7 million for the nine months ended September 30, 2026, primarily driven by a $178.4 million settlement payment from Moderna and $67.3 million in dividend income. This represents a major turnaround from a net loss of $29.7 million in the prior year period, significantly strengthening the company's cash position to $264.2 million.

Key figure
Net income $59.1M
7:33 AM ET 8-K
Loan & Debt Codexis, Inc. CDXS

Codexis $60M Debt Financing with Trinity Capital Inc.

Codexis entered into a $60 million Loan and Security Agreement with Trinity Capital, consisting of a $42.5 million initial tranche and $17.5 million in subsequent tranches. The debt is secured by substantially all company assets and carries a variable interest rate with an interest-only period extending up to November 2030. The facility provides capital to support operations while maintaining a financial covenant tied to the company's market capitalization.

Value
$60M
Counterparty
Trinity Capital Inc.
Term
5 years
7:33 AM ET 8-K
Financial Results Exagen Inc. XGN

Exagen Financial Results

Exagen Inc. reported third quarter 2026 revenue of $18.4 million, a 7% increase year-over-year, driven by growth in test volume and average selling price. The company reduced its net loss to $6.3 million for the quarter and reiterated its full-year 2026 revenue guidance of $72 million to $75 million.

Term
Q3 2026

“Our third quarter extends what is fast becoming a record year for Exagen, and our ability to execute against our vision is increasingly evident in the results. The team grew the business again, with test volume and ASP both ahead of the same period last year.”

John Aballi, President and Chief Executive Officer of Exagen
7:33 AM ET 8-K
M&A Deal Lci Industries LCII

Lci Industries M&A Deal with Patrick Industries, Inc.

LCI Industries announced that its Board of Directors unanimously rejected a revised unsolicited acquisition proposal from Monomoy Capital Partners for $104.50 per share in cash. The Board determined the offer substantially undervalues the company and reiterated its support for the pending merger with Patrick Industries, which it believes offers superior long-term value.

Counterparty
Patrick Industries, Inc.

“The LCI Board of Directors takes seriously its responsibility to best serve the interests of all LCI shareholders, and it is through that lens that we evaluate opportunities to maximize shareholder value, including proposals to merge with or acquire LCI.”

Ginnie Henkels, Chair of the Board of Directors

“Monomoy’s revised proposal is a modest increase to its initial offer and remains nowhere near LCI’s standalone value or the value creation opportunity of our combination with Patrick.”

Ginnie Henkels, Chair of the Board of Directors
7:32 AM ET 10-Q
Financial Results Energy Focus, Inc EFOI

Energy Focus Q3 2026 Results: Turns Profitable, Net Income $531K

Energy Focus, Inc. reported a significant increase in cash to $3.3 million as of September 30, 2026, compared to $1.1 million at year-end 2025, while inventories decreased from $2.9 million to $1.0 million. The company highlighted risks regarding its ability to continue as a going concern and its need for additional financing to maintain operations.

Key figure
Net income $531K
7:32 AM ET 8-K
Financial Results Ambiq Micro, Inc. AMBQ

Ambiq Micro Financial Results

Ambiq Micro reported Q3 2026 net sales of $38.1 million, a 110% year-over-year increase driven by strong demand for edge AI solutions. The company achieved its sixth consecutive quarter of sequential revenue growth and expanded its active customer base by 50%. Management issued Q4 revenue guidance of $43.5 million to $44.5 million, signaling continued acceleration in demand.

Term
Q3 2026

“We delivered our sixth consecutive quarter of sequential net sales growth supported by healthy customer demand and strong supply chain partnerships that enabled us to secure capacity and meet growing customer needs. With demand for edge AI accelerating, we expect to deliver a meaningful step-up in net sales in the fourth quarter and another year of strong growth in 2027.”

Fumihide Esaka, CEO of Ambiq

“We believe we are still in the early stages of a significant, multi-year shift toward greater intelligence at the edge. With our differentiated technology, growing portfolio and expanding customer base, we believe Ambiq is well positioned to capture the significant opportunity ahead.”

Fumihide Esaka, CEO of Ambiq
7:32 AM ET 8-K
Investor Presentation Entegris Inc ENTG

Entegris Investor Presentation

Entegris hosted its 2026 Capital Markets Day to outline a long-term growth strategy targeting a 15% revenue CAGR and 35% adjusted operating margins. Alongside the presentation, the company announced a new $500 million share repurchase authorization and a planned 10% increase to its quarterly dividend starting in 2027.

7:31 AM ET 8-K
Financial Results Arbutus Biopharma Corp ABUS

Arbutus Biopharma Financial Results

Arbutus Biopharma reported Q3 2026 financial results, highlighting a strong cash position of $337.5 million following a $178.4 million settlement payment from Moderna. The company also announced expanded patent infringement litigation against Pfizer and BioNTech in Japan and Canada regarding its LNP technology.

Term
Q3 2026

“This has been a busy and productive quarter for the Arbutus team. I would like to congratulate our finance team, which successfully returned a substantial portion of Moderna’s first patent infringement payment to shareholders, and our R&D team, for achieving the lift of the 2023 U.S. FDA clinical hold on our oral PD-L1 inhibitor, AB-101, following a successful Phase 1 trial abroad.”

Lindsay Androski, President and CEO
7:31 AM ET Form 4
Insider Buying Tronox Holdings plc TROX

Tronox Holdings Director Peter Johnston Buys $52.6K of Stock

Peter Johnston, Director, bought 20,000 shares of Tronox Holdings plc at $2.63 a share, worth $52.6K in total on Nov 9, 2026. Shares held after the trade: 224,461 (+9.8%).

Value
$52.6K
Shares
20,000
Price
$2.63
Role
Director
Holding change
+9.8%
Trade date
Nov 9, 2026
7:31 AM ET 8-K
Financial Results Kustom Entertainment, Inc. KUST

Kustom Entertainment Financial Results

Kustom Entertainment reported its first quarter as a pure-play live entertainment and ticketing company following the divestiture of its legacy video business. Total revenue from continuing operations grew 57% to $2.7 million, and the company achieved net income of $2.3 million, significantly bolstered by a $5.0 million gain from discontinued operations.

Term
Q3 2026

“The third quarter was our first full quarter operating exclusively as a live entertainment and ticketing company, and the results show the strength of the business we have built. A 57% revenue expansion in continuing operations, driven by surging TicketSmarter transaction volume, demonstrates the scalability of our platform.”

Stanton E. Ross, Chief Executive Officer of Kustom Entertainment, Inc.
7:30 AM ET 8-K
Financial Results Vireo Growth Inc. VREOF

Vireo Growth Financial Results

Vireo Growth reported Q3 2026 GAAP revenue of $253.7 million, a 177% increase year-over-year driven by recent M&A activity. The company achieved an annualized revenue run rate exceeding $1 billion and ended the quarter with $106.8 million in cash. Management highlighted the continued execution of its consolidation strategy and the pending merger with Planet 13.

Term
Q3 2026
7:29 AM ET 8-K
Loan & Debt Pyxus International, Inc. PYYX

Pyxus International Debt Financing Update with Pyxus Holdings, Inc.

Pyxus International and its subsidiary Pyxus Holdings have commenced a private exchange offer and consent solicitation for any and all of their outstanding 8.50% Senior Secured Notes due 2027. Holders who tender notes will receive a combination of new floating rate senior secured notes and shares of common stock valued at $3.25 per share. The transaction aims to restructure existing debt by extending maturities and amending restrictive covenants and collateral requirements.

Counterparty
Pyxus Holdings, Inc.
Term
through 2027
7:28 AM ET 8-K
Financial Results Energy Focus, Inc EFOI

Energy Focus Financial Results

Energy Focus reported Q3 2026 financial results with net sales of $4.8 million, a 481% increase year-over-year driven by the expansion of its Uninterruptible Power Supply (UPS) business in Taiwan. The company achieved profitability with net income of $0.5 million compared to a net loss in the prior year period, supported by higher commercial sales and a $184 thousand customs duty refund.

Term
Q3 2026
7:25 AM ET 8-K
Financial Results Cellectar Biosciences, Inc. CLRB

Cellectar Biosciences Financial Results

Cellectar Biosciences reported financial results for the third quarter of 2026, highlighting progress toward a planned accelerated approval filing for iopofosine I 131 in Waldenström macroglobulinemia (WM). The company remains on track to file its NDA with the FDA in the first half of 2027 and expects to dose the first patients in its Phase 3 confirmatory trial in Q1 2027.

Term
Q3 2026

“We remain focused on executing the clinical, regulatory and operational activities necessary to position iopofosine I 131 for potential registration and commercialization in Waldenström macroglobulinemia, and we believe our third quarter progress represents a significant step toward that goal.”

James Caruso, president and chief executive officer of Cellectar Biosciences

“To further maximize the long-term value of the program, we have initiated our Phase 1b dosimetry trial, which we believe offers an important opportunity to further characterize iopofosine I 131 across WM treatment settings, including first and second line.”

James Caruso, president and chief executive officer of Cellectar Biosciences
7:25 AM ET 8-K
Financial Results Autolus Therapeutics plc AUTL

Autolus Therapeutics Financial Results

Autolus Therapeutics reported Q3 2026 financial results, highlighted by $41.2 million in AUCATZYL net product revenue, a 95% year-over-year increase. The company raised its full-year 2026 revenue guidance for AUCATZYL to meet or exceed $150 million, driven by increased demand and manufacturing efficiencies that improved gross margins to 57%.

“We delivered another strong quarter of AUCATZYL revenue, primarily driven by growth within existing authorized treatment centers as physicians gain positive experience with the therapy, and supported by real-world data reported through the ROCCA consortium.”

Dr. Christian Itin, Chief Executive Officer

“AUCATZYL’s performance in adult r/r B-ALL is a key near-term value driver. Longer term, we believe expanding obe-cel across all stages of ALL and into autoimmune indications offers meaningful opportunities for scalable growth, leveraging its favorable profile and Autolus’ proven manufacturing and commercial capabilities.”

Dr. Christian Itin, Chief Executive Officer
7:24 AM ET 8-K
Leadership Change Commercial Metals Co CMC

Commercial Metals Leadership Change

Paul J. Lawrence notified the company of his decision to retire as Senior Vice President and CFO effective January 15, 2027, after which he will serve as a Special Advisor through June 2027. Kenji Hashimoto, formerly of Global Infrastructure Partners and Amazon, has been appointed to succeed him, initially joining as Deputy CFO on November 16, 2026. Hashimoto's employment agreement includes a base salary of $675,000 with cash and equity incentive eligibility.

7:21 AM ET 10-Q
Financial Results Scholar Rock Holding Corp SRRK

Scholar Rock Holding Q3 2026 Results: Net Loss of $107M, Loss Widens

Scholar Rock Holding Corp reported a net loss of $322.6 million for the nine months ended September 30, 2026, compared to $287.0 million in the prior year. The company recorded its first product revenue of $0.57 million in Q3 2026, while total liabilities increased significantly to $277.3 million due to new long-term debt financing.

Key figure
Net loss $107M
7:21 AM ET 10-Q
Financial Results 908 Devices Inc. MASS ▶ Call

908 Devices Q3 2026 Results: Net Loss of $4.58M, Loss Narrows

908 Devices Inc. reported total revenue of $18.95 million for the third quarter of 2026, a 35% increase year-over-year. Despite the revenue growth, the company recorded a net loss of $4.58 million for the quarter, though this was a significant improvement from the $14.98 million net loss in the prior year period.

Key figure
Net loss $4.58M
7:16 AM ET 10-Q
Financial Results Passage BIO, Inc. PASG

Passage BIO Q3 2026 Results: Net Loss of $4.72M, Loss Narrows

Passage Bio reported a net loss of $20.1 million for the nine months ended September 30, 2026, as it began winding down its gene therapy programs and entered into a merger agreement. Total assets decreased significantly from $62.3 million at year-end 2025 to $20.8 million, primarily due to the reduction in cash and the termination of lease assets.

Key figure
Net loss $4.72M
7:15 AM ET 8-K
Financial Results CalciMedica, Inc. CALC

CalciMedica Financial Results

CalciMedica reported third quarter 2026 financial results, ending the period with $13.8 million in cash which is expected to fund operations into the second half of 2027. The company highlighted clinical progress in its pulmonary hypertension and acute pancreatitis programs, with Phase 1b data for Auxora expected in mid-2027. Additionally, the company completed a 1-for-5 reverse stock split in August 2026 to regain Nasdaq compliance.

Term
3 years

“We continue to advance our pulmonary hypertension strategy, with data from the Auxora Phase 1b proof-of-concept trial in PH and the CM5480 IND submission both anticipated in mid-2027. Preclinical models suggest CRAC channel inhibitors may provide a differentiated approach in pulmonary hypertension by targeting multiple disease drivers, including right ventricular dysfunction, which is the principal cause of mortality and not directly targeted by existing therapies.”

Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica
7:13 AM ET 6-K
Financial Results Legend Biotech Corp LEGN

Legend Biotech Q3 2026 Results: Turns Profitable, Net Income $51.7M

Legend Biotech reported a significant turnaround for Q3 2026, achieving a net income of $51.7 million compared to a net loss of $39.6 million in the prior year, driven by higher CARVYKTI collaboration revenue and lower R&D and administrative expenses. Total revenue grew to $359.5 million, and the company achieved an operating income of $46.8 million.

Key figure
Net income $51.7M
7:11 AM ET 10-Q
Financial Results Palladyne AI Corp. PDYN ▶ Call

Palladyne AI Q3 2026 Results: Net Loss of $12M, Loss Widens

Palladyne AI Corp. reported a significant revenue increase to $8.56 million for the third quarter of 2026, up from $0.86 million in the prior year, driven by its AI/ML technology commercialization efforts. Despite this growth, the company incurred a net loss from operations of $38.72 million for the first nine months of 2026 as it continues to invest heavily in research, development, and general administrative scaling.

Key figure
Net loss $12M
7:11 AM ET 10-Q
Financial Results Olema Pharmaceuticals, Inc. OLMA

Olema Pharmaceuticals Q3 2026 Results: Net Loss of $73.6M, Loss Widens

Olema Pharmaceuticals reported a net loss of $189.9 million for the first nine months of 2026, compared to $116.4 million in the prior year, driven by a significant increase in research and development expenses. The company maintained a strong liquidity position with $413.8 million in cash, cash equivalents, and marketable securities as of September 30, 2026.

Key figure
Net loss $73.6M
7:11 AM ET 10-Q
Financial Results Upstream Bio, Inc. UPB

Upstream Bio Q3 2026 Results: Net Loss of $41.2M, Loss Widens

Upstream Bio reported a net loss of $121.5 million for the nine months ended September 30, 2026, compared to $101.0 million in the prior year, driven primarily by increased research and development expenses for its lead candidate, verekitug. The company's cash, cash equivalents, and short-term investments totaled $207.4 million as of September 30, 2026, down from $341.5 million at the end of 2025.

Key figure
Net loss $41.2M
7:11 AM ET 10-Q
Financial Results Sionna Therapeutics, Inc. SION

Sionna Therapeutics Q3 2026 Results: Net Loss of $32.4M, Loss Widens

Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis, specifically targeting the NBD1 domain. The company reports significant operating losses and anticipates needing substantial additional funding to advance its lead dual combination candidate, SION-451 + SION-2222, through clinical trials.

Key figure
Net loss $32.4M
7:11 AM ET 8-K
Divestiture Scholar Rock Holding Corp SRRK

Scholar Rock Holding Divestiture to BioNTech US Inc. for $205M

Scholar Rock agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to BioNTech US Inc. for $205 million in cash. The voucher was originally awarded by the FDA following the approval of ISEMBYLD for the treatment of spinal muscular atrophy. The transaction is subject to customary closing conditions and regulatory clearance under the Hart-Scott-Rodino Act.

Value
$205M
Counterparty
BioNTech US Inc.

“The third quarter was a defining period for Scholar Rock, marked by the FDA approval and U.S. launch of ISEMBYLD, the world’s first and only muscle-targeted therapy for children and adults living with SMA. We are very encouraged by the early ISEMBYLD launch dynamics in the U.S., where the breadth of early demand across SMA treatment centers, physicians, and patients reinforces the significant unmet need in the SMA community.”

David L. Hallal, Chairman and Chief Executive Officer of Scholar Rock
7:10 AM ET 8-K
Financial Results LENSAR, Inc. LNSR

LENSAR Financial Results

LENSAR reported third quarter 2026 financial results, highlighted by a 17% year-over-year increase in recurring revenue to $12.6 million despite a slight 1% decline in total revenue due to seasonal factors. The company expanded its ALLY System installed base to 225 units and reported a total laser installed base of 450 systems. While the company saw a net loss of $4.7 million, Adjusted EBITDA improved to $1.7 million compared to a loss in the prior year period.

Term
Q3 2026

“In-line with the expectations we shared in August, our third quarter results reflected the typical summer seasonality during which surgical scheduling and purchasing decisions contribute to a more measured pace of activity, leading to a sequential decline from a very strong second quarter.”

Nick Curtis, President and CEO of LENSAR

“Total revenue declined 1% year-over-year due to lower system sales against a robust number of sold systems in the prior year period, which was partially offset by growth in both procedure volume and recurring revenue.”

Nick Curtis, President and CEO of LENSAR

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.